Complexes
US-9777030-B2 · Oct 3, 2017 · US
US10081609B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10081609-B2 |
| Application number | US-201414772284-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 14, 2014 |
| Priority date | Mar 15, 2013 |
| Publication date | Sep 25, 2018 |
| Grant date | Sep 25, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention provides methods of inducing proliferation of and/or differentiating cells comprising contacting cells with compounds within the methods of the invention. The present invention further provides cells obtainable by the methods of the invention. Liver disease affects more than 500 million people worldwide. Organ transplantation is the gold standard for treatment of liver failure, but organ shortages are acute.
Opening claim text (preview).
What is claimed is: 1. A method of inducing differentiation of one or more induced pluripotent stem cell (iPS cell)-derived, immature hepatocyte cells (iHep cells), the method comprising: contacting the one or more iHep cells with compound 105 (N,N′-(methylenebis(4,1-phenylene))diacetamide); or a pharmaceutically acceptable salt thereof; wherein said contacting with the compound induces differentiation of the one or more immature iHep cells into mature hepatocytes. 2. The method of claim 1 , wherein the mature hepatocytes derived from the one or more iHep cells contacted with compound 105 express elevated levels of albumin in culture. 3. The method of claim 1 , wherein the mature hepatocytes derived from the one or more iHep cells contacted with compound 105 express minimal levels of alpha fetoprotein (AFP) in culture. 4. The method of claim 1 , wherein the mature hepatocytes derived from the one or more iHep cells contacted with compound 105 express elevated levels of CYP34A and CYP2A6 activity in culture. 5. The method of claim 1 , wherein the one or more iHep cells are human iHep cells. 6. The method of claim 1 , wherein the one or more iHep cells is contacted with compound 105 ex vivo. 7. A method of inducing differentiation of one or more induced pluripotent stem cell (iPS cell)-derived endothelial cells, the method comprising contacting the one or more iPS cell-derived endothelial cells with compound 105 (N,N′-(methylenebis(4,1-phenylene)) diacetamide), or a pharmaceutically acceptable salt thereof, wherein said contacting with the compound induces differentiation of the one or more iPS cell-derived endothelial cells to produce a population of more mature nitric oxide-producing endothelial cells. 8. The method of claim 7 , wherein the one or more iPS cell-derived endothelial cells is contacted with compound 105 ex vivo.
Hepatocytes · CPC title
Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes · CPC title
Basic fibroblast growth factor (bFGF, FGF-2) · CPC title
Liver; Hepatocytes · CPC title
Knock-in vertebrates, e.g. humanised vertebrates · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.